Pharmacokinetic-pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers

Br J Clin Pharmacol. 1999 Oct;48(4):510-2. doi: 10.1046/j.1365-2125.1999.00047.x.

Abstract

Aims: To describe the pharmacokinetic-pharmacodynamic modelling of the psychomotor and mnesic effects of a single 2 mg oral dose of lorazepam in healthy volunteers.

Methods: This was a randomized double-blind, placebo-controlled two-way cross-over study. The effect of lorazepam was examined with the following tasks: choice reaction time, immediate and delayed cued recall of paired words and immediate and delayed free recall and recognition of pictures.

Results: The mean calculated EC50 values derived from the PK/PD modelling of the different tests ranged from 12.2 to 15.3 ng ml-1. On the basis of the statistical comparison of the EC50 values, the delayed recall trials seemed to be more impaired than the immediate recall trials; similar observations were made concerning the recognition vs recall tasks.

Conclusions: The parameter values derived from PK/PD modelling, and especially the EC50 values, may provide sensitive indices that can be used, rather than the raw data derived from pharmacodynamic measurements, to compare CNS effects of benzodiazepines.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Amnesia, Anterograde / etiology
  • Anti-Anxiety Agents / blood
  • Anti-Anxiety Agents / pharmacokinetics*
  • Anti-Anxiety Agents / pharmacology*
  • Cross-Over Studies
  • Double-Blind Method
  • Humans
  • Lorazepam / blood
  • Lorazepam / pharmacokinetics*
  • Lorazepam / pharmacology*
  • Memory / drug effects*
  • Memory, Short-Term / drug effects
  • Time Factors

Substances

  • Anti-Anxiety Agents
  • Lorazepam